BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang M, Xia F, Wei Y, Wei X. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res 2020;8:30. [PMID: 34321455 DOI: 10.1038/s41413-020-00105-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Matsugaki A, Kimura Y, Watanabe R, Nakamura F, Takehana R, Nakano T. Impaired Alignment of Bone Matrix Microstructure Associated with Disorganized Osteoblast Arrangement in Malignant Melanoma Metastasis. Biomolecules 2021;11:131. [PMID: 33498283 DOI: 10.3390/biom11020131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kim JW, Lee KK, Park KW, Kim M, Lee CS. Genetically Modified Ferritin Nanoparticles with Bone-Targeting Peptides for Bone Imaging. Int J Mol Sci 2021;22:4854. [PMID: 34063731 DOI: 10.3390/ijms22094854] [Reference Citation Analysis]
3 Göbel A, Dell'Endice S, Jaschke N, Pählig S, Shahid A, Hofbauer LC, Rachner TD. The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. Int J Mol Sci 2021;22:5078. [PMID: 34064859 DOI: 10.3390/ijms22105078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther 2021;6:379. [PMID: 34744168 DOI: 10.1038/s41392-021-00778-y] [Reference Citation Analysis]
5 Shapiro CL. Bone-modifying Agents (BMAs) in Breast Cancer. Clin Breast Cancer 2021:S1526-8209(21)00087-2. [PMID: 34045175 DOI: 10.1016/j.clbc.2021.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang J, Du X, Wang X, Xiao H, Jing N, Xue W, Dong B, Gao WQ, Fang YX. Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis. Cancer Lett 2022;526:76-90. [PMID: 34801597 DOI: 10.1016/j.canlet.2021.11.017] [Reference Citation Analysis]
7 Long M, Liu X, Huang X, Lu M, Wu X, Weng L, Chen Q, Wang X, Zhu L, Chen Z. Alendronate-functionalized hypoxia-responsive polymeric micelles for targeted therapy of bone metastatic prostate cancer. J Control Release 2021;334:303-17. [PMID: 33933517 DOI: 10.1016/j.jconrel.2021.04.035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Antognelli C, Marinucci L, Frosini R, Macchioni L, Talesa VN. Metastatic Prostate Cancer Cells Secrete Methylglyoxal-Derived MG-H1 to Reprogram Human Osteoblasts into a Dedifferentiated, Malignant-like Phenotype: A Possible Novel Player in Prostate Cancer Bone Metastases. Int J Mol Sci 2021;22:10191. [PMID: 34638532 DOI: 10.3390/ijms221910191] [Reference Citation Analysis]
9 Hinz N, Jücker M. AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review. Cancers (Basel) 2021;13:2287. [PMID: 34064589 DOI: 10.3390/cancers13102287] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Sun X, Li K, Hase M, Zha R, Feng Y, Li BY, Yokota H. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling. Theranostics 2022;12:929-43. [PMID: 34976221 DOI: 10.7150/thno.66148] [Reference Citation Analysis]
11 Liu Y, Yang P, Pi Y, Jiang L, Zhong X, Cheng J, Xiang Y, Wei J, Li L, Yi Z, Cai H, Zhao Z. Automatic identification of suspicious bone metastatic lesions in bone scintigraphy using convolutional neural network. BMC Med Imaging 2021;21:131. [PMID: 34481459 DOI: 10.1186/s12880-021-00662-9] [Reference Citation Analysis]
12 Shi S, Wang H, Liu X, Xiao J. Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database. Transl Cancer Res 2021;10:5191-203. [PMID: 35116369 DOI: 10.21037/tcr-21-1507] [Reference Citation Analysis]
13 Li S, Wang W. Extracellular Vesicles in Tumors: A Potential Mediator of Bone Metastasis. Front Cell Dev Biol 2021;9:639514. [PMID: 33869189 DOI: 10.3389/fcell.2021.639514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Pin F, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonetto A, Bonewald LF. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Lett 2021;520:80-90. [PMID: 34233150 DOI: 10.1016/j.canlet.2021.06.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Li D, He C, Ye F, Ye E, He H, Chen G, Zhang J. p62 Overexpression Promotes Bone Metastasis of Lung Adenocarcinoma out of LC3-Dependent Autophagy. Front Oncol 2021;11:609548. [PMID: 34094898 DOI: 10.3389/fonc.2021.609548] [Reference Citation Analysis]
16 Niu Y, Yang H, Yu Z, Gao C, Ji S, Yan J, Han L, Huo Q, Xu M, Liu Y. Intervention with the Bone-Associated Tumor Vicious Cycle through Dual-Protein Therapeutics for Treatment of Skeletal-Related Events and Bone Metastases. ACS Nano 2022. [PMID: 35077154 DOI: 10.1021/acsnano.1c08269] [Reference Citation Analysis]
17 Choi JY, Lee YS, Shim DM, Lee YK, Seo SW. GNAQ knockdown promotes bone metastasis through epithelial-mesenchymal transition in lung cancer cells. Bone Joint Res 2021;10:310-20. [PMID: 33993733 DOI: 10.1302/2046-3758.105.BJR-2020-0262.R3] [Reference Citation Analysis]
18 Chen Q, Zhou L, Chen F, Hu A, Wang K, Liang H, Dong J. Forkhead box F2 as a novel prognostic biomarker and potential therapeutic target in human cancers prone to bone metastasis: a meta-analysis. J Int Med Res 2021;49:3000605211002372. [PMID: 33845605 DOI: 10.1177/03000605211002372] [Reference Citation Analysis]
19 Di Pompo G, Errani C, Gillies R, Mercatali L, Ibrahim T, Tamanti J, Baldini N, Avnet S. Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis. Front Cell Dev Biol 2021;9:678532. [PMID: 34124067 DOI: 10.3389/fcell.2021.678532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Xu J, Ma L, Wang D, Yang J. Uncarboxylated osteocalcin promotes proliferation and metastasis of MDA-MB-231 cells through TGF-β/SMAD3 signaling pathway. BMC Mol Cell Biol 2022;23:18. [PMID: 35413833 DOI: 10.1186/s12860-022-00416-7] [Reference Citation Analysis]
21 Goel S, Bhatia V, Kundu S, Biswas T, Carskadon S, Gupta N, Asim M, Morrissey C, Palanisamy N, Ateeq B. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression. Nat Commun 2021;12:5325. [PMID: 34493733 DOI: 10.1038/s41467-021-25623-2] [Reference Citation Analysis]
22 Kitayama K, Kawamoto T, Kawakami Y, Hara H, Takemori T, Fujiwara S, Yahiro S, Miyamoto T, Mifune Y, Hoshino Y, Kakutani K, Matsumoto T, Matsushita T, Niikura T, Kuroda R, Akisue T. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis. Int J Oncol 2021;59:97. [PMID: 34713296 DOI: 10.3892/ijo.2021.5277] [Reference Citation Analysis]
23 Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Iyer V, Velikyan I, Sörensen J. Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer. European J Hybrid Imaging 2022;6. [DOI: 10.1186/s41824-022-00127-4] [Reference Citation Analysis]
24 Andriessen AS, Donnelly CR, Ji RR. Reciprocal interactions between osteoclasts and nociceptive sensory neurons in bone cancer pain. Pain Rep 2021;6:e867. [PMID: 33981921 DOI: 10.1097/PR9.0000000000000867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sun M, Huang K, Luo X, Li H. Templated Three-Dimensional Engineered Bone Matrix as a Model for Breast Cancer Osteolytic Bone Metastasis Process. Int J Nanomedicine 2021;16:8391-403. [PMID: 35002234 DOI: 10.2147/IJN.S338609] [Reference Citation Analysis]
26 Bock N, Kryza T, Shokoohmand A, Röhl J, Ravichandran A, Wille ML, Nelson CC, Hutmacher DW, Clements JA. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci Adv 2021;7:eabg2564. [PMID: 34193425 DOI: 10.1126/sciadv.abg2564] [Reference Citation Analysis]
27 Schwartz E, Reichert Z, Van Poznak C. Pharmacologic management of metastatic bone disease. Bone 2020;:115735. [PMID: 33171313 DOI: 10.1016/j.bone.2020.115735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Fischetti T, Di Pompo G, Baldini N, Avnet S, Graziani G. 3D Printing and Bioprinting to Model Bone Cancer: The Role of Materials and Nanoscale Cues in Directing Cell Behavior. Cancers (Basel) 2021;13:4065. [PMID: 34439218 DOI: 10.3390/cancers13164065] [Reference Citation Analysis]
29 Bădilă AE, Rădulescu DM, Niculescu AG, Grumezescu AM, Rădulescu M, Rădulescu AR. Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review. Cancers (Basel) 2021;13:4229. [PMID: 34439383 DOI: 10.3390/cancers13164229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]